Recruiting Spinal Muscular Atrophy Studies in Nashville
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person'...
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig w...
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cel...
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC....
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (...
About Spinal Muscular Atrophy Clinical Trials in Nashville
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.
There are currently 5 spinal muscular atrophy clinical trials recruiting participants in Nashville, TENNESSEE. These studies are seeking a combined 785 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Antares Therapeutics, Inc and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Spinal Muscular Atrophy Clinical Trials in Nashville — FAQ
Are there spinal muscular atrophy clinical trials in Nashville?
Yes, there are 5 spinal muscular atrophy clinical trials currently recruiting in Nashville, TENNESSEE. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Nashville?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you about next steps.
Are clinical trials in Nashville free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nashville studies also compensate for your time and travel.
What spinal muscular atrophy treatments are being tested?
The 5 active trials in Nashville are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.
Data updated March 2, 2026 from ClinicalTrials.gov